KEYNOTE-B36
IDE approval
The FDA has approved our investigational device exemption application to initiate the KEYNOTE-B36 trial evaluating TTFields together with pembrolizumab in NSCLC, conducted in collaboration with MSD. We also announced the formation of a scientific steering committee.
Learn more
update on
LUNAR trial
We announced an update regarding our phase 3 pivotal LUNAR trial of Tumor Treating Fields as a treatment for stage 4 non-small cell lung cancer following platinum failure.
Learn more
Novocure at
AACR Annual Meeting
This year’s American Association for Cancer Research Annual Meeting will highlight 26 presentations suggesting broad applicability of Tumor Treating Fields.
Learn more
first patient enrolled
in TRIDENT
The first patient has been enrolled in our global phase 3 TRIDENT trial in newly diagnosed glioblastoma.
Learn more
the story
of Novocure
We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 1,000 employees and operations in the U.S., Europe and Asia. With more than 20 years of research and many significant milestones, we believe we are only beginning.
Learn More
we can leverage physics to fight cancer
Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division.
OUR THERAPY
explore our clinical pipeline
Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.
OUR PIPELINE
we are dedicated to making a difference in cancer
Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.
PATIENT-FORWARD